Inter-individual variation in imatinib disposition: any role for prevalent variants of CYP1A2, CYP2C8, CYP2C9, and CYP3A5 in Nigerian CML patients?-Reference-Cited by-同舟云学术

Inter-individual variation in imatinib disposition: any role for prevalent variants of CYP1A2, CYP2C8, CYP2C9, and CYP3A5 in Nigerian CML patients?

Published:2018-05-09 Issue:1 Volume:60 Page:216-221
ISSN:1042-8194
Container-title:Leukemia & Lymphoma
language:en
Short-container-title:Leukemia & Lymphoma

Author:

Adehin Ayorinde¹,Adeagbo Babatunde A.¹^ORCID,Kennedy Martin A.²^ORCID,Bolaji Oluseye O.¹^ORCID,Olugbade Tiwalade A.¹,Bolarinwa Rahman A.³,Durosinmi Muheez A.³

Affiliation:

1. Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Obafemi Awolowo University, Ile-Ife, Nigeria;

2. Department of Pathology and Carney Centre for Pharmacogenomics, University of Otago, Christchurch, New Zealand;

3. Department of Haematology and Immunology, Obafemi Awolowo University, Ile-Ife, Nigeria

Publisher

Informa UK Limited

Subject

Cancer Research,Oncology,Hematology

Link

https://www.tandfonline.com/doi/pdf/10.1080/10428194.2018.1466291

Reference25 articles.

1. Frequency of Major Molecular Responses to Imatinib or Interferon Alfa plus Cytarabine in Newly Diagnosed Chronic Myeloid Leukemia

2. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial

3. Pharmacokinetic/pharmacodynamic correlation and blood-level testing in imatinib therapy for chronic myeloid leukemia

4. CYP3A activity influences imatinib response in patients with chronic myeloid leukemia: a pilot study on in vivo CYP3A activity

5. Influence of CYP3A5*3 and ABCB1 C3435T on clinical outcomes and trough plasma concentrations of imatinib in Nigerians with chronic myeloid leukaemia

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Therapeutic drug monitoring and pharmacogenetics to tune imatinib exposure in gastrointestinal stromal tumor patients: hurdles and perspectives for clinical implementation;Pharmacogenomics;2023-12

2. Management of chronic myeloid leukaemia: current treatment options, challenges, and future strategies;Hematology;2023-04-20

3. Cytochromes P450 2C8 and 3A Catalyze the Metabolic Activation of the Tyrosine Kinase Inhibitor Masitinib;Chemical Research in Toxicology;2022-09-01

4. External evaluation of population pharmacokinetic models of imatinib in adults diagnosed with chronic myeloid leukaemia;British Journal of Clinical Pharmacology;2021-11-26

5. Pharmacogenomics of Impaired Tyrosine Kinase Inhibitor Response: Lessons Learned From Chronic Myelogenous Leukemia;Frontiers in Pharmacology;2021-06-28